S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:FENC

Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis

$11.12
+0.03 (+0.27%)
(As of 03/28/2024 ET)
Today's Range
$11.04
$11.37
50-Day Range
$8.82
$11.12
52-Week Range
$6.30
$11.92
Volume
120,083 shs
Average Volume
167,035 shs
Market Capitalization
$300.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.75

Fennec Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.6% Upside
$16.75 Price Target
Short Interest
Bearish
8.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.01mentions of Fennec Pharmaceuticals in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$336,516 Sold Last Quarter
Proj. Earnings Growth
407.69%
From $0.13 to $0.66 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.77 out of 5 stars

Medical Sector

464th out of 939 stocks

Biological Products, Except Diagnostic Industry

76th out of 158 stocks

FENC stock logo

About Fennec Pharmaceuticals Stock (NASDAQ:FENC)

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

FENC Stock Price History

FENC Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Q4 2023 Fennec Pharmaceuticals Inc Earnings Call
FENC Apr 2024 12.500 call
See More Headlines
Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FENC
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.75
High Stock Price Target
$18.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+50.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-16,050,000.00
Pretax Margin
-175.57%

Debt

Sales & Book Value

Annual Sales
$21.25 million
Book Value
($0.10) per share

Miscellaneous

Free Float
23,998,000
Market Cap
$300.68 million
Optionable
Optionable
Beta
0.35
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

FENC Stock Analysis - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FENC shares.
View FENC analyst ratings
or view top-rated stocks.

What is Fennec Pharmaceuticals' stock price target for 2024?

4 analysts have issued twelve-month price targets for Fennec Pharmaceuticals' shares. Their FENC share price targets range from $16.00 to $18.00. On average, they expect the company's stock price to reach $16.75 in the next year. This suggests a possible upside of 50.6% from the stock's current price.
View analysts price targets for FENC
or view top-rated stocks among Wall Street analysts.

How have FENC shares performed in 2024?

Fennec Pharmaceuticals' stock was trading at $11.22 at the start of the year. Since then, FENC stock has decreased by 0.9% and is now trading at $11.12.
View the best growth stocks for 2024 here
.

When is Fennec Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FENC earnings forecast
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) announced its earnings results on Monday, November, 6th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. The company had revenue of $6.52 million for the quarter, compared to the consensus estimate of $5.22 million. During the same quarter last year, the business posted ($0.31) earnings per share.

What guidance has Fennec Pharmaceuticals issued on next quarter's earnings?

Fennec Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20.7 million-$21.2 million, compared to the consensus revenue estimate of $19.6 million.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.22%), Vanguard Group Inc. (4.22%), DG Capital Management LLC (3.98%), AIGH Capital Management LLC (1.22%), Gendell Jeffrey L (1.04%) and Worth Venture Partners LLC (0.52%). Insiders that own company stock include Chris A Rallis, Robert Andrade and Rosty Raykov.
View institutional ownership trends
.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FENC) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners